[Congress] 2019 J.P. Morgan Health Care Investor Conference - January 7-10, 2019 - San Francisco - USA -

2019 J.P. Morgan Health Care Investor Conference - January 7–10, 2019 San Francisco

We will be there to introduce our expertise in macrocyclization of small Lead-like molecules & our R&D kinase inhibitor programs available under adhoc agreements.

Fabrice Viviani - Experimentation Strategic Activity Director will be available to fix meetings. 


Let's meet !

[Congress] I4ID - Immunotherapies for Infectious Diseases Congress - 10-11 December 2018 - Lyon - France

I4ID - Immunotherapies for infectious diseases congress - 10-11 December, Lyon

Come and meet Emilie Soulier– Business Account Manager - to discuss your project and find out how Oncodesign’s immuno services can support your program!

Let's meet!


[Congress] ESMO - Immuno-Oncology Congress - 13-16 December – Geneva - Switzerland

ESMO Immuno-Oncology Congress – 13-16 Decembre – Genève, Suisse

Come at the poster session & meet Marc Hillairet – Study Director – to discover the latest data presented in partnership with IPSEN:

"Cabozantinib in combination with anti-PD immune checkpoint inhibitor in syngeneic tumor mouse models"

Marc Hillairet de Boisferon, PhD, Study Director, Oncodesign
Sophie Rolland, Research Manager, Oncology Therapeutic Area, R&D, Translational Sciences, IPSEN

Let's meet to discuss my project!  

[Congress] MedChem 2018- 23 November - Namur - Belgium

MedChem 2018 -  23 November – Namur,  Belgium

 Come meet Petra Blom at our poster session & discover how macrocyclisation is systematically applied within all Oncodesign’s projects leading to a Nanocyclix® platform:

“Nanocyclix®: next generation kinase therapeutics: A chemocentric approach for the discovery of selective kinase inhibitors”

I read the abstract!

By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.